Loading...
Header Logo
Keywords
Last Name
Institution

AMIR A JAZAERI

TitleAssociate Professor
InstitutionMD Anderson
DepartmentGynecological Oncology & Reproductive Medicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer. 2019 May 03; 7(1):118. PMID: 31053161.
      View in: PubMed
    2. Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier RS, Charabaty A, Dadu R, Jazaeri A, Lashner B, Wang Y. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019 Apr 02; 7(1):93. PMID: 30940209.
      View in: PubMed
    3. Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer. 2019 Feb 06; 7(1):31. PMID: 30728076.
      View in: PubMed
    4. Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol. 2018 12; 151(3):407-413. PMID: 30366646.
      View in: PubMed
    5. Roszik J, Ring KL, Wani KM, Lazar AJ, Yemelyanova AV, Soliman PT, Frumovitz M, Jazaeri AA. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol. 2018; 9:2102. PMID: 30283446.
      View in: PubMed
    6. Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380. PMID: 30213435.
      View in: PubMed
    7. Johnson C, Jazaeri AA. Diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in Ovarian Cancer: A Series of Case Vignettes. Clin Ther. 2018 03; 40(3):389-394. PMID: 29519715.
      View in: PubMed
    8. Jazaeri AA. Immunotherapy in ovarian cancer: where are we now, and where are we going? Clin Adv Hematol Oncol. 2017 Nov; 15(11):851-853. PMID: 29200418.
      View in: PubMed
    9. Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. J Cutan Pathol. 2017 Dec; 44(12):1080-1086. PMID: 28901560.
      View in: PubMed
    10. Pakish JB, Jazaeri AA. Immunotherapy in Gynecologic Cancers: Are We There Yet? Curr Treat Options Oncol. 2017 08 24; 18(10):59. PMID: 28840453.
      View in: PubMed
    11. Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik J. Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Front Immunol. 2017; 8:689. PMID: 28670312.
      View in: PubMed
    12. Nelson BH, Jazaeri AA. Immunotherapy for gynecological cancers: opportunities abound. Gynecol Oncol. 2017 06; 145(3):411-412. PMID: 28552394.
      View in: PubMed
    13. Kumar P, Dillon LW, Shibata Y, Jazaeri AA, Jones DR, Dutta A. Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation. Mol Cancer Res. 2017 09; 15(9):1197-1205. PMID: 28550083.
      View in: PubMed
    14. Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA. Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecol Oncol Rep. 2017 May; 20:93-96. PMID: 28393092.
      View in: PubMed
    15. Pires ES, D'Souza RS, Needham MA, Herr AK, Jazaeri AA, Li H, Stoler MH, Anderson-Knapp KL, Thomas T, Mandal A, Gougeon A, Flickinger CJ, Bruns DE, Pollok BA, Herr JC. Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget. 2017 Feb 28; 8(9):16099. PMID: 28403580.
      View in: PubMed
    16. Ring KL, Yemelyanova AV, Soliman PT, Frumovitz MM, Jazaeri AA. Potential immunotherapy targets in recurrent cervical cancer. Gynecol Oncol. 2017 06; 145(3):462-468. PMID: 28233576.
      View in: PubMed
    17. Yuan Y, Guo B, Munsell M, Lu K, Jazaeri A. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Stat Med. 2016 09 30; 35(22):3892-906. PMID: 27112322.
      View in: PubMed
    18. Zamarin D, Jazaeri AA. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol. 2016 Apr; 141(1):86-94. PMID: 27016233.
      View in: PubMed
    19. Ring KL, Pakish J, Jazaeri AA. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. Cancer J. 2016 Mar-Apr; 22(2):101-7. PMID: 27111905.
      View in: PubMed
    20. Varadaraj A, Patel P, Serrao A, Bandyopadhay T, Lee NY, Jazaeri AA, Huang Z, Murphy SK, Mythreye K. Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. Neoplasia. 2015 Nov; 17(11):826-38. PMID: 26678910.
      View in: PubMed
    21. Pires ES, D'Souza RS, Needham MA, Herr AK, Jazaeri AA, Li H, Stoler MH, Anderson-Knapp KL, Thomas T, Mandal A, Gougeon A, Flickinger CJ, Bruns DE, Pollok BA, Herr JC. Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget. 2015 Oct 06; 6(30):30194-211. PMID: 26327203.
      View in: PubMed
    22. Qiao Y, Quinlan AR, Jazaeri AA, Verhaak RG, Wheeler DA, Marth GT. SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. Genome Biol. 2014 Aug 26; 15(8):443. PMID: 25160522.
      View in: PubMed
    23. Jividen K, Movassagh MJ, Jazaeri A, Li H. Two methods for establishing primary human endometrial stromal cells from hysterectomy specimens. J Vis Exp. 2014 May 23; (87). PMID: 24894444.
      View in: PubMed
    24. Scalici JM, Harrer C, Allen A, Jazaeri A, Atkins KA, McLachlan KR, Slack-Davis JK. Inhibition of a4ß1 integrin increases ovarian cancer response to carboplatin. Gynecol Oncol. 2014 Feb; 132(2):455-61. PMID: 24378876.
      View in: PubMed
    25. Jazaeri AA, Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, Smith PG, Milhollen MA, Berger AJ, Dutta A. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer Ther. 2013 Oct; 12(10):1958-67. PMID: 23939375.
      View in: PubMed
    26. Courtney-Brooks M, Scalici J, Henretta MS, Modesitt SC, Jazaeri AA, Cantrell LA, Duska LR. Vulvar necrotizing soft tissue infection: A review of a multi-disciplinary surgical emergency and management in the modern era. Gynecol Oncol Case Rep. 2013; 5:6-9. PMID: 24371682.
      View in: PubMed
    27. Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens R, Maxwell GL, Jazaeri A, Risinger JI, Rubin JS, Niederhuber J. Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene. 2013 Jul 04; 32(27):3246-53. PMID: 22890324.
      View in: PubMed
    28. Bae-Jump V, Jazaeri A. Summary of the 2012 American Association for Cancer Research (AACR) Annual Meeting. Gynecol Oncol. 2012 Aug; 126(2):174-5. PMID: 22588179.
      View in: PubMed
    29. Courtney-Brooks M, Tellawi AR, Scalici J, Duska LR, Jazaeri AA, Modesitt SC, Cantrell LA. Frailty: an outcome predictor for elderly gynecologic oncology patients. Gynecol Oncol. 2012 Jul; 126(1):20-4. PMID: 22522190.
      View in: PubMed
    30. Jazaeri AA, Bryant JL, Park H, Li H, Dahiya N, Stoler MH, Ferriss JS, Dutta A. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia. 2011 Oct; 13(10):899-911. PMID: 22028616.
      View in: PubMed
    31. Lachance JA, Choudhri AF, Sarti M, Modesitt SC, Jazaeri AA, Stukenborg GJ. A nomogram for estimating the probability of ovarian cancer. Gynecol Oncol. 2011 Apr; 121(1):2-7. PMID: 21269667.
      View in: PubMed
    32. Timofeev J, Galgano MT, Stoler MH, Lachance JA, Modesitt SC, Jazaeri AA. Appendiceal pathology at the time of oophorectomy for ovarian neoplasms. Obstet Gynecol. 2010 Dec; 116(6):1348-53. PMID: 21099601.
      View in: PubMed
    33. Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM, Risinger JI, Jazaeri A, Niederhuber J. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle. 2010 Nov 01; 9(21):4387-98. PMID: 20980827.
      View in: PubMed
    34. Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A. Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer. Gynecol Oncol. 2010 Aug 01; 118(2):189-95. PMID: 20462630.
      View in: PubMed
    35. Terai K, Abbas T, Jazaeri AA, Dutta A. CRL4(Cdt2) E3 ubiquitin ligase monoubiquitinates PCNA to promote translesion DNA synthesis. Mol Cell. 2010 Jan 15; 37(1):143-9. PMID: 20129063.
      View in: PubMed
    36. Ferriss JS, Atkins KA, Lachance JA, Modesitt SC, Jazaeri AA. Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. Int J Gynecol Cancer. 2010 Jan; 20(1):120-5. PMID: 20130512.
      View in: PubMed
    37. Jazaeri AA, Slack-Davis JK. The promise of antiangiogenic therapy for ovarian cancer. Cancer Biol Ther. 2009 Dec; 8(23):2273-4. PMID: 19907207.
      View in: PubMed
    38. Greene DP, Ferriss JS, Jazaeri AA. Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report. Cancer Chemother Pharmacol. 2010 Jul; 66(2):265-7. PMID: 19844714.
      View in: PubMed
    39. Jazaeri AA. Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease. Mol Oncol. 2009 Apr; 3(2):151-6. PMID: 19383376.
      View in: PubMed
    40. Bland AE, Stone R, Heuser C, Shu J, Jazaeri A, Shutter J, Atkins K, Rice L. A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas. Int J Gynecol Cancer. 2009 Feb; 19(2):261-5. PMID: 19396006.
      View in: PubMed
    41. Lachance JA, Shutter J, Atkins KA, Stoler MH, Rice LW, Jazaeri AA. Utilization of a uniform grading system for interpreting serous ovarian cancer. Am J Obstet Gynecol. 2008 Aug; 199(2):189.e1-6. PMID: 18501326.
      View in: PubMed
    42. Lachance JA, Darus CJ, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA. A cost comparison of two strategies for treating stage IB2 cervical cancer. Int J Gynecol Cancer. 2008 Mar-Apr; 18(2):274-8. PMID: 18334009.
      View in: PubMed
    43. Young JL, Jazaeri AA, Darus CJ, Modesitt SC. Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol. 2008 Apr; 109(1):140-5. PMID: 18275990.
      View in: PubMed
    44. Lachance JA, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA. A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma. Gynecol Oncol. 2008 Jan; 108(1):77-83. PMID: 17936341.
      View in: PubMed
    45. Darus CJ, Callahan MB, Nguyen QN, Pastore LM, Schneider BF, Rice LW, Jazaeri AA. Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma. Int J Gynecol Cancer. 2008 Jul-Aug; 18(4):730-5. PMID: 17949426.
      View in: PubMed
    46. Modesitt SC, Jazaeri AA. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin Pharmacother. 2007 Oct; 8(14):2293-305. PMID: 17927484.
      View in: PubMed
    47. Callahan MB, Lachance JA, Stone RL, Kelsey J, Rice LW, Jazaeri AA. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol. 2007 Aug; 197(2):199.e1-4; discussion 199.e4-5. PMID: 17689649.
      View in: PubMed
    48. Young JL, Jazaeri AA, Lachance JA, Stoler MH, Irvin WP, Rice LW, Andersen WA, Modesitt SC. Cervical adenocarcinoma in situ: the predictive value of conization margin status. Am J Obstet Gynecol. 2007 Aug; 197(2):195.e1-7; discussion 195.e7-8. PMID: 17689647.
      View in: PubMed
    49. Everett EN, French AE, Stone RL, Pastore LM, Jazaeri AA, Andersen WA, Taylor PT. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol. 2006 Aug; 195(2):568-74; discussion 574-6. PMID: 16890558.
      View in: PubMed
    50. Rice LW, Stone RL, Xu M, Galgano M, Stoler MH, Everett EN, Jazaeri AA. Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors. Am J Obstet Gynecol. 2006 Apr; 194(4):1119-26; discussion 1126-8. PMID: 16580307.
      View in: PubMed
    51. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005 Sep 01; 11(17):6300-10. PMID: 16144934.
      View in: PubMed
    52. Irvin W, Evans SR, Andersen W, Jazaeri A, Taylor P, Stoler M, Pastore L, Rice L. The utility of HPV DNA triage in the management of cytological AGC. Am J Obstet Gynecol. 2005 Aug; 193(2):559-65; discussion 565-7. PMID: 16098895.
      View in: PubMed
    53. Jazaeri AA, Chandramouli GV, Aprelikova O, Nuber UA, Sotiriou C, Liu ET, Ropers HH, Yee CJ, Boyd J, Barrett JC. BRCA1-mediated repression of select X chromosome genes. J Transl Med. 2004 Sep 21; 2(1):32. PMID: 15383145.
      View in: PubMed
    54. Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res. 2003 Oct 15; 9(13):4811-8. PMID: 14581352.
      View in: PubMed
    55. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003 Sep 02; 100(18):10393-8. PMID: 12917485.
      View in: PubMed
    56. Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GV, Gershenson DM, Liu ET. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog. 2003 Feb; 36(2):53-9. PMID: 12557260.
      View in: PubMed
    57. Risinger JI, Maxwell GL, Chandramouli GV, Jazaeri A, Aprelikova O, Patterson T, Berchuck A, Barrett JC. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res. 2003 Jan 01; 63(1):6-11. PMID: 12517768.
      View in: PubMed
    58. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst. 2002 Jul 03; 94(13):990-1000. PMID: 12096084.
      View in: PubMed
    59. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 2002; 4(3):R3. PMID: 12052255.
      View in: PubMed
    60. Sotiriou C, Khanna C, Jazaeri AA, Petersen D, Liu ET. Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn. 2002 Feb; 4(1):30-6. PMID: 11826185.
      View in: PubMed
    61. Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA, Rice LW. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene. 2001 Oct 18; 20(47):6965-9. PMID: 11687977.
      View in: PubMed
    62. Jazaeri A, Satija II. Localization transition in incommensurate non-Hermitian systems. Phys Rev E Stat Nonlin Soft Matter Phys. 2001 Mar; 63(3 Pt 2):036222. PMID: 11308756.
      View in: PubMed
    63. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res. 2000 Jan 15; 60(2):245-8. PMID: 10667568.
      View in: PubMed
    64. Jazaeri O, Shupnik MA, Jazaeri AA, Rice LW. Expression of estrogen receptor alpha mRNA and protein variants in human endometrial carcinoma. Gynecol Oncol. 1999 Jul; 74(1):38-47. PMID: 10385549.
      View in: PubMed
    65. Rice LW, Jazaeri AA, Shupnik MA. Estrogen receptor mRNA splice variants in pre- and postmenopausal human endometrium and endometrial carcinoma. Gynecol Oncol. 1997 Apr; 65(1):149-57. PMID: 9103405.
      View in: PubMed
    66. Philpot BD, Jazaeri AA, Brunjes PC. The development of serotonergic projections to the olfactory bulb of Monodelphis domestica (the grey, short-tailed opossum). Brain Res Dev Brain Res. 1994 Feb 18; 77(2):265-70. PMID: 8174233.
      View in: PubMed
    67. Brunjes PC, Jazaeri A, Sutherland MJ. Olfactory bulb organization and development in Monodelphis domestica (grey short-tailed opossum). J Comp Neurol. 1992 Jun 22; 320(4):544-54. PMID: 1378458.
      View in: PubMed
    68. Frailty. Obstetrical and Gynecological Survey. 68:30-32.
    69. Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. Neoplasia (United States). 17:826-838.
    70. Immune checkpoint inhibitors in the treatment of gynecologic malignancies. Cancer Journal (United States). 22:101-107.
    71. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecologic Oncology. 141:86-94.
    72. BRCA1-mediated repression of select X chromosome genes. Journal of Translational Medicine. 2.
    73. Vulvar necrotizing soft tissue infection. Gynecologic Oncology Case Reports. 5:6-9.
    74. Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget. 6:30194-30211.
    JAZAERI's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description